{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:33:45Z","timestamp":1793763225810,"version":"4.6.1"},"reference-count":18,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZonMW \u2018voorwaardelijke vergoedingen program\u2019"},{"name":"Goodlife Pharma BV"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,9]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The double blind, multicentre, randomised, placebo-controlled GAG-therapy Efficacy Trial Solution for Bladder pain syndrome\/Interstitial cystitis (GETSBI) study aims to evaluate the efficacy of intravesical glycosaminoglycans therapy with hyaluronic acid and chondroitin sulfate in symptomatic bladder pain syndrome\/interstitial cystitis (BPS\/IC) patients with Hunner lesions. This trial encompasses multiple methodologies, including a standard randomised controlled trial (RCT), a cross-over trial and an N-of-1 trial. An N-of-1 trial is a multiple crossover trial, usually randomised and often blinded, conducted in a single patient (1). The N-of-1 methodology is, however, only valid under the condition that there is no carry-over effect, meaning a carry-over of effect from an a-priori intervention period into the placebo period. Therefore, it is important to examine any potential carry-over effects to determine the validity of the study protocol concerning the N-of-1 trial part and thereby justifying recruitment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Interim analysis for potential carry-over effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Secondary care, 21 participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>21 participants, participants concluded part one from the GETSBI study at time of this analysis (October 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measure<\/jats:title>\n                    <jats:p>The primary outcome of the study is the change from baseline in pain intensity, measured by visual analogue scale (VAS) pain. To assess for carry-over effects, the placebo responses on VAS pain were compared between groups with (n=10) and without (n=11) potential carry-over effects. The threshold for a clinically relevant carry-over effect was set at a difference on VAS pain &gt;0.50 points. Data were analysed using descriptive statistics, T-tests, effect sizes and 95% CI. Statistical significance was set at \u03b1=0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean baseline VAS pain did not differ (p=0.12) between group A (n=10, VAS 7.52, SD=0.52) and group B (n=11, VAS 6.02, SD=2.47). The mean placebo responses on VAS pain for groups A and B were 0.97 (SD=1.85) and 1.47 (SD=1.81), respectively. The mean carry-over effect was 0.50 (SD=1.83), which was not statistically significant with a 95%\u2009CI of \u22121.17 to 2.17 and p=0.5369.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This interim analysis shows that an N-of-1 trial probably will be feasible for evaluating non-curative treatment efficacy in chronic disease using only half the patients as are required for a classic RCT. Future analysis will provide a direct comparison of outcomes between the RCT, crossover and the N-of-1 part for a complete evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05518864\">NCT05518864<\/jats:ext-link>\n                      (GETSBI study).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092757","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:25:27Z","timestamp":1749097527000},"page":"e092757","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Carry-over effects in GAG therapy efficacy trial solution for bladder pain syndrome\/interstitial cystitis (GETSBI study): an interim analysis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05518864","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6416-7892","authenticated-orcid":false,"given":"Charlotte","family":"van Ginkel","sequence":"first","affiliation":[{"name":"Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M M","family":"Groenewoud","sequence":"additional","affiliation":[{"name":"Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Hoogeboom","sequence":"additional","affiliation":[{"name":"Radboud Institute for Health Sciences, IQ healthcare, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heesakkers","sequence":"additional","affiliation":[{"name":"Department of Urology, Maastricht UMC+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025121221345224000_15.6.e092757.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068546","article-title":"Study protocol of a multicentre double-blind RCT, comparing a traditional RCT with an aggregated N-of-1 trial: GAG therapy Efficacy Trial Solution for Bladder pain syndrome\/Interstitial cystitis (GETSBI study)","volume":"13","author":"van Ginkel","year":"2023","journal-title":"BMJ Open"},{"key":"2025121221345224000_15.6.e092757.2","unstructured":"Howick J , Library) I , Glasziou P , et al . The oxford 2011 levels of evidence cebm. 2011. Available: https:\/\/www.cebm.net\/wp-content\/uploads\/2014\/06\/CEBM-Levels-of-Evidence-2.1.pdf"},{"key":"2025121221345224000_15.6.e092757.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1793","article-title":"CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025121221345224000_15.6.e092757.4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13629-023-00382-5","article-title":"Interstiti\u00eble cystitis, voorbij BPS\/IC. Etiologie, epidemiologie en klinische presentatie. Een overzicht vanuit praktijk en literatuur","volume":"13","author":"Weidenaar","year":"2023","journal-title":"Tijdschr Urol"},{"key":"2025121221345224000_15.6.e092757.5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-5347(17)69067-0","article-title":"Interstitial cystitis; report of 223 cases (204 women and 19 men)","volume":"61","author":"HAND","year":"1949","journal-title":"J Urol"},{"key":"2025121221345224000_15.6.e092757.6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0022-5347(17)36120-7","article-title":"The natural history of interstitial cystitis: a survey of 374 patients","volume":"149","author":"Koziol","year":"1993","journal-title":"J Urol"},{"key":"2025121221345224000_15.6.e092757.7","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000145102.40773.43"},{"key":"2025121221345224000_15.6.e092757.8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.juro.2008.06.035","article-title":"The role of cystoscopy in the diagnosis of Hunner\u2019s ulcer disease","volume":"180","author":"Braunstein","year":"2008","journal-title":"J Urol"},{"key":"2025121221345224000_15.6.e092757.9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00365599.2012.689008","article-title":"Clinical characteristics differ considerably between phenotypes of bladder pain syndrome\/interstitial cystitis","volume":"46","author":"Logadottir","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"2025121221345224000_15.6.e092757.10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00192-012-2003-9","article-title":"Pain in interstitial cystitis\/bladder pain syndrome: do characteristics differ in ulcerative and non-ulcerative subtypes?","volume":"24","author":"Killinger","year":"2013","journal-title":"Int Urogynecol J"},{"key":"2025121221345224000_15.6.e092757.11","unstructured":"Kravitz R , Duan N , The DEcIDE Methods Center N-of-1 Guidance Panel . Design and implementation of N-of-1 trials: a user\u2019s guide. 2014."},{"key":"2025121221345224000_15.6.e092757.12","first-page":"21","article-title":"P - value, a true test of statistical significance? A cautionary note","volume":"6","author":"Dahiru","year":"2008","journal-title":"Ann Ib Postgrad Med"},{"key":"2025121221345224000_15.6.e092757.13","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2016.1154108"},{"key":"2025121221345224000_15.6.e092757.14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/09602011.2013.815636","article-title":"Visual analysis in single case experimental design studies: brief review and guidelines","volume":"24","author":"Lane","year":"2014","journal-title":"Neuropsychol Rehabil"},{"key":"2025121221345224000_15.6.e092757.15","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90059-7"},{"key":"2025121221345224000_15.6.e092757.16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780071204"},{"key":"2025121221345224000_15.6.e092757.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.17.2203"},{"key":"2025121221345224000_15.6.e092757.18","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31818131e7"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:34:59Z","timestamp":1765604099000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-092757"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092757","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}